Bavarian Nordic has signed a manufacturing agreement with SII, expanding its strategic partnership through a contract for its ...

Vima's selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.

Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin to treat peritumoral brain oedema in Japan.

In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation of Wegovy.

The investment in China follows similar outlays by the drugmaker in other regions as it prepares for high orforglipron demand.

Dubai is building life sciences clusters and research hubs, aiming to be a resilient healthcare and innovation center in a region facing ongoing conflict.

The FDA has granted approval for the expanded use of GSK’s Wellcovorin to treat CFD in patients with a confirmed variant in the FOLR1 gene.

J&J has announced the US FDA approval for the combination of Tecvayli and Darzalex Faspro for adults with RRMM.

Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to CAR designs tailored for myeloid ...

Idorsia has signed an exclusive deal with Pharmalink Drug Store to distribute and commercialise its Quviviq therapy in various Gulf states.

This ends a drawn out legal battle brought by Genevant and Arbutus against Moderna under a week before the jury trial was set ...